AXSM 株価推移チャート
AXSM 財務
Axsome Therapeutics Inc
$223.06
-0.28%
$-0.63
終値： May 05, 16:00:00 GMT-4
$223
-0.02%
$-0.06
アフターマーケット：May 05, 20:00:00 GMT-4
戻る
Axsome Therapeutics Inc (AXSM) 財務
主要データ
前終値
$223.7
始値
$226.06
当日レンジ
$222.33 - $231
52週レンジ
$96.09 - $223
取引高
814.3K
平均取引高
607.3K
配当利回り
--
1株当たり利益(TTM)
-3.69
時価総額
$11.4B
AXSMとは何ですか？
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The firm's commercial products include Auvelity, Sunosi and Symbravo. The company is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
